Jack Aiello

Board Member

Jack Aiello is a former Silicon Valley high technology executive living in San Jose, CA. Jack was diagnosed with multiple myeloma in 1995 and has had three transplants for his condition. While the treatments have given him extended survival, he has had disabling side effects. After retiring, Jack has become a leading myeloma support group leader and traveled the US and overseas to attend medical conference, patient forums and inspire advocacy among patients.

Scott Riccio

Scott is currently Head of Patient and Professional Engagement at Alder Biopharmaceuticals, a biotechnology company based in Bothell, WA, dedicated to transforming the migraine treatment paradigm through the discovery, development, and commercialization of novel therapeutic antibodies.  Scott’s focus at Alder is on leading the development and execution of Alder’s overarching advocacy strategy including developing, implementing and leading both patient and professional advocacy engagement across the commercial portfolio, clinical development and drug discovery.

Before taking the position at Alder, Scott was Head of Advocacy at Juno Therapeutics where he led Juno’s efforts to build and develop the company’s partnerships with external stakeholders including; patient advocacy groups, medical and nursing professional organizations, health policy groups, and community partners.  He was also a member of Juno’s commercial senior leadership team and helped build and leverage strong internal cross-functional partnerships to ensure patient and caregiver voices were heard and included throughout company decision-making processes.

Prior to Juno, Scott held leadership positions in areas of Advocacy, Education, and Patient Access at Food Allergy Research & Education (“FARE”), Synageva Biopharma, the Leukemia & Lymphoma Society (“LLS”), and Dendreon Corporation.  At Synageva, his role as Vice-President of Global Patient Advocacy also included overseeing the development of the company’s government affairs and public policy functions with a focus on ensuring patient access and the inclusion of rare disease patients’ perspectives as part of policy in healthcare.

Before taking the position at Synageva, Scott was Senior Vice-President for Patient Access, Education, & Advocacy at The Leukemia & Lymphoma Society, working out of the Office of Public Policy in Washington, D.C.  Scott’s responsibilities for the Society included building a stronger Mission presence for the Society across the country, building and overseeing a team of regional strategic leaders to focus on assessing patient needs and deploying resources to meet those needs, and serving as external Mission spokesperson for LLS in supporting campaign and development initiatives. Strategic resources under Scott’s oversight include patient outreach and engagement, HCP/provider relations, patient and professional education, and advocacy.

Prior to LLS, Scott was Associate Director for Advocacy and Health Policy for Dendreon Corporation, focusing on ensuring patient access to innovative anti-cancer therapies while helping strengthen the organizations he worked with in the cancer advocacy community. His work also included outreach and engagement with payers/insurers and healthcare providers and a special focus on underserved groups disproportionately impacted by prostate cancer, specifically African American and Veteran populations.

Scott’s background includes time as the founder and president of a 501(c)3 advocacy organization focused on health policy, particularly FDA/drug development timelines and processes, as well as a decade of experience consulting with global financial institutions during his time at Morningstar Associates, LLC.  He holds a B.A. in political science from Middlebury College and an M.B.A. with a dual concentration in entrepreneurship and strategy from the University of Chicago.